Lung cancer is the leading cause of cancer death in men and women worldwide. Brain
metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of …

Purpose It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non …

Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

The purpose of this study was to demonstrate the beneficial effect of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of leptomeningeal …

Tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) were previously
the standard first-line treatments for lung cancers with activating EGFR mutations. The first …

Lung cancer remains a leading cause of mortality with 1.69 million deaths worldwide.
Activating mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 …

Simple Summary The management of non-small cell lung cancer with a common EGFR
mutation has evolved over the past decades. While frontline use of second-or third …

Controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival
benefit prompted us to explore the possible risk factors for brain metastasis (BM) during the …

Patients with non-small cell lung cancer (NSCLC) and de novo brain metastasis (BM) have
poor prognosis. We aim to investigate the characteristic of brain magnetic resonance (MR) …

Background and Purpose Epidermal growth factor receptor (EGFR)-mutant lung cancers are
associated with a high risk of developing brain metastases (BM). Craniocerebral …